Navigation Links
Talecris Biotherapeutics Hires Nimish Shah as Vice President, Federal Government Relations
Date:4/29/2010

Shah will serve as a member of the federal affairs lobbying and policy team that represents Talecris to the legislative and executive branches of government in Washington, D.C.

Research Triangle Park, NC (Vocus) April 29, 2010 -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Nimish Shah has joined the public affairs department as vice president, federal government relations.

Shah will serve as a member of the federal affairs lobbying and policy team that represents Talecris to the legislative and executive branches of government in Washington, D.C. He will collaborate with members of the public affairs team to lead Talecris’ political action committee and to educate internal and external audiences on key policy initiatives that affect Talecris’ business.

Shah brings a diverse set of skills and experience in the fields of public policy, law and business, including strategic oversight and implementation of government affairs outreach programs, regulatory and reimbursement policy development, and patient advocacy and alliance partnerships.

Before joining Talecris, Shah served as senior director and head of Takeda Pharmaceuticals’ D.C. office, where he developed and led the company’s lobbying, policy and patient advocacy functions. Prior to his position at Takeda, Shah served as director of public policy and manager of public policy and federal government affairs at Roche Pharmaceuticals. Shah spent the first twelve years of his career practicing law in Philadelphia and Washington, D.C., respectively.

Nimish earned his Bachelor of Arts degree in International Relations from Rutgers University in New Brunswick, N.J. He earned his Juris Doctor from the Rutgers School of Law and an Executive Master of Business degree from the Rutgers School of Business. He also participated in the International Law Program at Regent’s College in London, England.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.

Contact:
Talecris Corporate Communications
Becky Levine, 919-316-6590

###

Read the full story at http://www.prweb.com/releases/Talecris_Biotherapeutics/Nimish_Shah/prweb3944394.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Northwest Biotherapeutics Inc. Appoints Market Media Connect as Communications Agency of Record
2. Integrative Logic Hires Sharon Maloney as Director of Business Intelligence
3. Linfield College's Adult Degree Program Hires New Associate Dean of Nursing for Distance Learning
4. Silverchair Learning Systems Enhances Product Expertise with New Hires
5. Stone Soup Technology Hires Former Scoop Magazine Publisher Melanie Feltman
6. The Logo Loft Hires Laid-Off Sales Executive Increasing Sales for Company by 15% Despite the Recession
7. Reliv International Hires Director of Strategic Development
8. Native Remedies and PetAlive.com Hires TransMedia Group to Herald Herbal for People and Pets
9. Aegis Health Group Hires Pearson Talbert as Chief Development Officer
10. CBCA Names Tim Reed as Vice President, Human Resources
11. Statement by Irwin Redlener, MD, President, Childrens Health Fund on Passage of a Health Care Reform Package by the House
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Talecris Biotherapeutics Hires Nimish Shah as Vice President, Federal Government Relations 
(Date:12/2/2016)... , ... December 02, 2016 , ... ... Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health radio ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... Gardens, FL (PRWEB) , ... November 30, 2016 ... ... eating disorder and mental health treatment has announced the opening of a new ... specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, both males ...
(Date:11/30/2016)... ... 2016 , ... In recent policy debates, increasing costs of ... and system stakeholders in many states. To help them understand this growth, today ... Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a policymaker or ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... the Dow Jones Industrial Average edged 0.36% higher, to finish ... 0.35%. Losses were broad based as six out of nine ... research reports on the following Services equities: Myriad Genetics Inc. ... QGEN ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
Breaking Medicine Technology: